Chimeric antigen receptor T-cell therapy in pediatric neurological autoimmune diseases: mechanisms, clinical applications, and future perspectives
Frontiers in Pediatrics · 25.03.2026 · 14
DOI: 10.3389/fped.2026.1740566 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pediatrics, online erschienen am 25.03.2026. Verfasst von Weihao Ling und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Children's Hospital of Nanjing Medical University, Nanjing, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pediatric neurological autoimmune diseases (PNADs) are a result of immune system abnormalities that target the central and peripheral nervous systems, leading to various neurological dysfunctions in children. The limitations of current immunotherapies underscore the necessity for more efficacious treatment interventions. The objective of this review is to examine the fundamental principles, recent advancements, and clinical applications of chimeric antigen receptor (CAR) T cell therapy in the treatment of pediatric neurological autoimmune diseases (PNADs). By specifically targeting and reducing pathogenic B cells, CAR-T therapy has the potential to reset the immune system. Growing evidence from preclinical animal studies, case reports, and early clinical trials suggests that CAR-T cell therapy has therapeutic potential in managing autoimmune diseases such as myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and systemic lupus erythematosus (SLE). However, several challenges remain, including the high cost of treatment, safety concerns such as cytokine release syndrome and neurotoxicity, and a lack of long-term safety data in pediatric populations. Future research should prioritize optimizing the management and evaluation model for the entire process, as well as refining CAR design and development, to enhance the safe and effective clinical application of CAR T-cell therapy in patients with PNADs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Children's Hospital of Nanjing Medical University, Nanjing, China.
- Department of Neurology, Children's Hospital of Soochow University, Suzhou, China.
- Department of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Zitieren
APA
Ling, W., Xu, C., Tang, J., Lu, S., & Wu, C. (2026). Chimeric antigen receptor T-cell therapy in pediatric neurological autoimmune diseases: mechanisms, clinical applications, and future perspectives. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.1740566
Vancouver
Ling W, Xu C, Tang J, Lu S, Wu C. Chimeric antigen receptor T-cell therapy in pediatric neurological autoimmune diseases: mechanisms, clinical applications, and future perspectives. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.1740566
BibTeX
@article{Ling2026,
author = {Ling, Weihao and Xu, Chen and Tang, Jihong and Lu, Shifeng and Wu, Chunfeng},
title = {Chimeric antigen receptor T-cell therapy in pediatric neurological autoimmune diseases: mechanisms, clinical applications, and future perspectives},
journal = {Frontiers in Pediatrics},
year = {2026},
volume = {14},
doi = {10.3389/fped.2026.1740566}
}
EUVIMED